DE19813748A1 - Besserung der Dupuytren-Krankheit - Google Patents
Besserung der Dupuytren-KrankheitInfo
- Publication number
- DE19813748A1 DE19813748A1 DE19813748A DE19813748A DE19813748A1 DE 19813748 A1 DE19813748 A1 DE 19813748A1 DE 19813748 A DE19813748 A DE 19813748A DE 19813748 A DE19813748 A DE 19813748A DE 19813748 A1 DE19813748 A1 DE 19813748A1
- Authority
- DE
- Germany
- Prior art keywords
- collagenase
- use according
- dupuytren
- abc units
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000001708 Dupuytren contracture Diseases 0.000 title claims description 15
- 108060005980 Collagenase Proteins 0.000 claims description 39
- 102000029816 Collagenase Human genes 0.000 claims description 39
- 229960002424 collagenase Drugs 0.000 claims description 39
- 239000007924 injection Substances 0.000 claims description 21
- 238000002347 injection Methods 0.000 claims description 21
- 210000000811 metacarpophalangeal joint Anatomy 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 210000001503 joint Anatomy 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 210000003811 finger Anatomy 0.000 description 18
- 239000000872 buffer Substances 0.000 description 7
- 210000003195 fascia Anatomy 0.000 description 7
- 210000000651 myofibroblast Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000002435 tendon Anatomy 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 206010062575 Muscle contracture Diseases 0.000 description 3
- 208000006111 contracture Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000193159 Hathewaya histolytica Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001550206 Colla Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 108010013295 Microbial collagenase Proteins 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012897 dilution medium Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000002683 hand surgery Methods 0.000 description 1
- 229940027278 hetastarch Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004934 left little finger Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000004932 little finger Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000004933 right little finger Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/826,015 US6086872A (en) | 1997-03-27 | 1997-03-27 | Amelioration of dupuytren's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19813748A1 true DE19813748A1 (de) | 1998-10-01 |
Family
ID=25245473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19813748A Expired - Lifetime DE19813748A1 (de) | 1997-03-27 | 1998-03-27 | Besserung der Dupuytren-Krankheit |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6086872A (enExample) |
| AU (1) | AU733208B2 (enExample) |
| DE (1) | DE19813748A1 (enExample) |
| DK (1) | DK177324B1 (enExample) |
| FR (2) | FR2772273B1 (enExample) |
| GB (1) | GB2323530B (enExample) |
| NO (1) | NO981388L (enExample) |
| SE (1) | SE522723C2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6958150B2 (en) | 1994-12-15 | 2005-10-25 | Advance Biofactures Of Curacao, N.V. | Reduction of adipose tissue |
| US6022539A (en) * | 1999-06-03 | 2000-02-08 | Advance Biofactures Of Curacao | Amelioration of peyronie's disease |
| GB0306165D0 (en) * | 2003-03-18 | 2003-04-23 | Delta G Ltd | Medical treatment |
| PL1846022T3 (pl) * | 2005-01-21 | 2016-06-30 | Univ New York State Res Found | Sposoby leczenia zarostowego zapalenia torebki stawowej |
| US20070224184A1 (en) * | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
| ITPD20050207A1 (it) | 2005-07-07 | 2007-01-08 | Fidia Farmaceutici | Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere |
| US7811560B2 (en) | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
| WO2008100833A2 (en) * | 2007-02-13 | 2008-08-21 | Auxilium International Holdings, Inc. | Production of recombinant collagenases colg and colh in escherichia coli |
| US10071143B1 (en) | 2007-05-03 | 2018-09-11 | The Research Foundation For The State University Of New York | Methods for non-surgical treatment of carpal tunnel syndrome |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| JP5649589B2 (ja) * | 2009-03-06 | 2015-01-07 | ハロザイム インコーポレイテッド | マトリックスメタロプロテアーゼ１の温度感受性突然変異体およびその使用 |
| WO2010111525A2 (en) | 2009-03-25 | 2010-09-30 | Agee, John, M., Trustee Of The John M. Agee Trust Of August 15, 1996 | Treatment of carpal tunnel syndrome by injection of the flexor retinaculum |
| EP2632446B1 (en) * | 2010-10-30 | 2018-12-12 | Oxford University Innovation Limited | Treatment for dupuytren's disease |
| WO2012125948A1 (en) | 2011-03-16 | 2012-09-20 | Biospecifics Technologies Corp. | Compositions and methods for producing clostridial collagenases |
| KR101921363B1 (ko) | 2011-07-20 | 2018-11-22 | 메디운드 리미티드 | 결합 조직 질환을 치료하기 위한 브로멜라인으로부터의 단백분해 추출물 |
| GB201119089D0 (en) | 2011-11-04 | 2011-12-21 | Isis Innovation | Treatment of musculoskeletal fibroproliferative disorders |
| EP4276180A3 (en) | 2012-01-12 | 2024-01-10 | Endo Global Ventures | Clostridium histolyticum enzyme |
| US20150079069A1 (en) * | 2012-04-30 | 2015-03-19 | Elastomics Ab | Methods for modification of tissues |
| WO2014066622A2 (en) | 2012-10-24 | 2014-05-01 | The Research Foundation For The State University Of New York | Use of collagenase to treat glaucoma |
| US20150196625A9 (en) | 2013-01-07 | 2015-07-16 | Rudolph D. Paladini | Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof |
| AU2014228477B2 (en) | 2013-03-15 | 2019-05-23 | Biospecifics Technologies Corporation | Treatment method and product for uterine fibroids using purified collagenase |
| CN103751102A (zh) | 2014-01-15 | 2014-04-30 | 上海交通大学 | 一种胶原酶温敏水凝胶及其制备方法和应用 |
| KR20250021648A (ko) | 2017-03-01 | 2025-02-13 | 엔도 오퍼레이션즈 리미티드 | 셀룰라이트를 평가하고 치료하기 위한 장치 및 방법 |
| WO2018183582A2 (en) | 2017-03-28 | 2018-10-04 | Endo Ventures Limited | Improved method of producing collagenase |
| US11872267B2 (en) | 2019-10-15 | 2024-01-16 | The Johns Hopkins University | Treatment of uterine fibroids using purified collagenase |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4338300A (en) * | 1981-02-05 | 1982-07-06 | The Regents Of The University Of California | Use of purified clostridial collangenase in the treatment of Peyronie's disease |
| US5173295A (en) * | 1990-10-05 | 1992-12-22 | Advance Biofactures Of Curacao, N.V. | Method of enhancing the regeneration of injured nerves and adhesive pharamaceutical formulation therefor |
| US5393792A (en) * | 1991-11-20 | 1995-02-28 | Advance Biofactures Of Curacao, N.V. | High dosage topical forms of collagenase |
| US5589171A (en) | 1994-08-22 | 1996-12-31 | Advance Biofactures Of Curacao | Treatment of Dupuytren's disease with collagenase |
-
1997
- 1997-03-27 US US08/826,015 patent/US6086872A/en not_active Ceased
-
1998
- 1998-03-11 GB GB9805050A patent/GB2323530B/en not_active Expired - Lifetime
- 1998-03-12 SE SE9800806A patent/SE522723C2/sv not_active IP Right Cessation
- 1998-03-18 FR FR9803320A patent/FR2772273B1/fr not_active Expired - Lifetime
- 1998-03-23 DK DKPA199800403A patent/DK177324B1/da not_active IP Right Cessation
- 1998-03-26 AU AU59661/98A patent/AU733208B2/en not_active Expired
- 1998-03-26 NO NO981388A patent/NO981388L/no not_active Application Discontinuation
- 1998-03-27 DE DE19813748A patent/DE19813748A1/de not_active Expired - Lifetime
-
2005
- 2005-03-30 US US11/094,753 patent/USRE39941E1/en not_active Expired - Lifetime
-
2011
- 2011-08-18 FR FR11C0033C patent/FR11C0033I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SE522723C2 (sv) | 2004-03-02 |
| DK40398A (da) | 1998-09-28 |
| FR11C0033I2 (fr) | 2012-03-16 |
| DK177324B1 (da) | 2013-01-07 |
| AU733208B2 (en) | 2001-05-10 |
| FR2772273A1 (fr) | 1999-06-18 |
| USRE39941E1 (en) | 2007-12-18 |
| GB2323530B (en) | 2001-10-10 |
| GB2323530A (en) | 1998-09-30 |
| SE9800806D0 (sv) | 1998-03-12 |
| AU5966198A (en) | 1998-10-01 |
| NO981388L (no) | 1998-09-28 |
| GB9805050D0 (en) | 1998-05-06 |
| US6086872A (en) | 2000-07-11 |
| NO981388D0 (no) | 1998-03-26 |
| SE9800806L (sv) | 1998-09-28 |
| FR2772273B1 (fr) | 2003-04-25 |
| FR11C0033I1 (enExample) | 2011-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19813748A1 (de) | Besserung der Dupuytren-Krankheit | |
| DE69534309T2 (de) | Medizinische verwendung von matrixmetallproteine-inhibitoren zur hemmung von gewebekontraktion | |
| DE60007001T2 (de) | Neurotoxine zur behandlung von pankreatischen krankheiten | |
| Kischer et al. | Alteration of hypertrophic scars induced by mechanical pressure | |
| DE69929361T2 (de) | Botulinumtoxine zur verstärkung der wundheilung | |
| DE69731955T2 (de) | Kombination von saurer protease-enzyme und saure puffers und ihre verwendung | |
| US4524065A (en) | Method for the prevention and treatment of scars with enzymes | |
| DE60100473T2 (de) | Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen | |
| EP1779862B1 (de) | Erythropoietin in subpolycythämischen dosen zur behandlung von diabetes | |
| DE60118859T2 (de) | Pharmazeutische Zusammensetzung enthaltend Trehalose zur ophthalmischen Verwendung | |
| DE3788231T2 (de) | Kosmetisches mittel und zusammensetzung zur behandlung der haut. | |
| DE3881364T2 (de) | Verfahren zur Herstellung und Zusammensetzungen von Kollagen-Derivaten. | |
| Finkelstein et al. | Recovery of muscle after different periods of denervation and treatments | |
| DE60310400T2 (de) | Botulinustoxine zur behandlung von priapismus | |
| Pfister et al. | Topical ascorbate decreases the incidence of corneal ulceration after experimental alkali burns. | |
| US6165983A (en) | Use of collagen for the treatment of degenerative articular processes | |
| DE19530832A1 (de) | Besserung der Dupuytren-Krankheit | |
| JPH11502513A (ja) | 糖尿病性ニューロパシーの処置方法 | |
| DE69328228T2 (de) | Wundheilmittel | |
| DE60212143T2 (de) | Verwendung von thrombin-peptidderivaten zur behandlung von chronischen hautulcera | |
| JP2020511548A (ja) | 治療用のボツリヌス神経毒素 | |
| DE69732616T2 (de) | Erhöhung der Migration oder Proliferation von Keratinocyten | |
| DE69008635T2 (de) | Augentropfen zur heilung einer wunde am hornhautepithelium. | |
| DE69818809T2 (de) | Verfahren zur behandlung von narbengewebe | |
| DE10221194A1 (de) | Hyaluronidasehaltiges Hautpflegemittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8127 | New person/name/address of the applicant |
Owner name: ADVANCE BIOFACTURES CORP., LYNBROOK, N.Y., US |
|
| 8172 | Supplementary division/partition in: |
Ref document number: 19861475 Country of ref document: DE Kind code of ref document: P |
|
| Q171 | Divided out to: |
Ref document number: 19861475 Country of ref document: DE Kind code of ref document: P |
|
| R071 | Expiry of right |